Summary
ARKG Chart
People also search for
Best-Performing ETF Areas of August
August delivered strong gains across shipping, crypto, precious metals, biotech, copper, uranium and cloud software ETFs.
ARKG: Caught In The Tech Sell-Off, But Here's Why The Dip Is Buyable
ARK Genomic Revolution ETF remains a buy as its valuation improves and technical support emerges after a 15% correction from July highs. ARKG's portfolio is concentrated in small- and mid-cap biotech, with top 10 holdings comprising 59% and a long-term EPS growth rate now at 10.7%. Despite weak seasonality and high volatility, ARKG's rising 200-day moving average and strong support at $34–$35 provide a favorable risk-reward setup.
ETF Showdown: ARKG vs GNOM, Which Genomics Fund Wins?
The ARK Genomic Revolution ETF (CBOE:ARKG) and the Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) look like siblings on any screener.
ARK Genomic Revolution ETF Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| DI David Izzi Brown, LISLE/CUMMINGS Inc. | 325 | $9,044.19 | $12,532 | $3,487.81 | 38.56% |
 Curtis Ellergodt Rothschild Investment LLC | 14,450 | $343,656.03 | $557,192 | $213,535.97 | 62.14% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 64,295 | $2.7M | $2.77M | $63,002.86 | 2.33% |
| TC Tyler Chaisson COMPASS CAPITAL Corp. /MA/ /ADV | 13,214 | $354,367.66 | $590,533.66 | $236,166 | 66.64% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 1,967 | $53,623.24 | $87,629.85 | $34,006.61 | 63.42% |
ARK Genomic Revolution ETF (ARKG) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has ARK Genomic Revolution ETF ever had a stock split?
ARK Genomic Revolution ETF Profile
| BATS Exchange | US Country |
Overview
The fund is a cutting-edge investment vehicle focusing on the burgeoning field of genomics, operating as an actively-managed exchange-traded fund (ETF). It seeks to capitalize on the transformative potential of genomics across various sectors, including healthcare, information technology, materials, energy, and consumer discretionary. By investing primarily in both domestic and foreign equity securities of companies at the forefront of the genomics revolution, the fund aims to offer investors unique exposure to this dynamic and rapidly evolving industry. Despite its concentrated theme, the fund maintains a broad perspective by integrating firms from multiple sectors that are instrumental in advancing genomics-related technologies and applications. It is non-diversified, indicating a focused investment strategy in companies specifically selected for their relevance to the genomics revolution.
Products and Services
- Equity Securities of Genomics Revolution Companies
This product is the centerpiece of the fund's investment strategy, comprising a significant portion of its assets in domestic and foreign equity securities of companies leading the genomics revolution. By focusing on sectors such as healthcare, information technology, materials, energy, and consumer discretionary, the fund targets entities that are integral to the advancement of genomics. This includes firms engaged in genetic sequencing, gene editing, biotechnological innovation, and other areas that contribute to the evolution of genomics.
